Abstract
The results of laboratory and clinical studies of cefoperazone (CPZ, T-1551), a new broad spectrum cephalosporin, were as follows;
1) Nineteen cases, aged from 2 weeks after birth to 59 years, with various cutaneous bacterial infections were treated with this antibiotic.
The daily dose was mainly 0.5 g per day in children and 2 g per day in adults, and was chiefly given by intramuscular injection in 2 divided doses for 3 to 17 days. The total dose of this antibiotic given in this study was 1.5-34g.
2) In several clinical isolates, namely 17 strains of Staphylococcus aureus, MIC of this antibiotic was determined with the dilute plate method. Its peak was shown at 3.13μg/ml in inoculum sized 106/ml and 6.25μg/ml in 108/ml, respectively.
3) Most of all cases caused by not only Staphylococcus aureus, but also gram-negative rods revealed excellent results in the administration of this drug.
The overall efficacy rate was 94.7%, i. e., excellent in 14 cases, good in 4 cases and fair in only one case.
4) No adverse reactions were noted.
